Global Hepatitis Drugs Market, By Drug Class (Interferon Alphas, HIV NRTIs, Nucleotide Polymerase/NS5A Inhibitor Combinations, Hepatitis C Protease/NS5A Inhibitor Combinations, NS5A Inhibitors, Nucleotide Polymerase Inhibitors, Nucleoside Analogue Antivirals, and Thrombopoiesis Stimulating Agents), By Disease Type (Hepatitis B, Hepatitis C, and Others), By Route of Administration (Oral and injection), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) was valued at US$ 21,148.3 million in 2019, and is projected to exhibit a CAGR of 3.2% over the forecast period (2019 - 2027), as highlighted in a new report published by Coherent Market Insights.
Increasing number of government initiatives aimed at expanding drug coverage is expected to drive growth of the market. For instance, in 2018, the Ministry of Health and Long-Term Care of Ontario announced that all patients are eligible for Ontario Drug Benefit (ODP) irrespective of severity of their disease. In the same year, Thunder Bay group, a company that provides HIV/AIDS/Hepatitis C education and support services, expand its presence into medicines, as a result of successful negotiations between provinces and drug manufacturers.
Moreover, availability of Hepatitis C drugs is expected to increase over the forecast period due to increasing drug development. Growth of the hepatitis drugs market is being driven by direct acting antivirals (DAAs), which aid the development of highly effective, INF-free hepatitis C drugs. The product pipeline of market players consists of dual as well as triple DDA combinational therapies against the hepatitis C virus. A combination of drugs is more effective for the treatment of hepatitis C as compared to single regimen. For instance, in 2016, Gilead submitted a new drug application of a fixed-dose combination SOF/VEL/voxilaprevir for treatment of HCV genotypes 1–6 to the U.S. FDA. Moreover, in January 2017, drug assessment of the SOF/VEL/voxilaprevir combination was granted by the European Medicines Agency (EMA).
Browse 38 Market Data Tables and 27 Figures spread through 173 Pages and in-depth TOC on "Hepatitis Drugs Market, By Drug Class (Interferon Alphas, HIV NRTIs, Nucleotide Polymerase/NS5A Inhibitor Combinations, Hepatitis C Protease/NS5A Inhibitor Combinations, NS5A Inhibitors, Nucleotide Polymerase Inhibitors, Nucleoside Analogue Antivirals and Thrombopoiesis Stimulating Agents), By Disease Type (Hepatitis B, Hepatitis C and Others), By Route of Administration (Oral and injection), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Global Forecast to 2026"
To know the latest trends and insights related to Hepatitis Drugs Market, click the link below:
https://www.coherentmarketinsights.com/market-insight/hepatitis-drugs-market-2977
Additionally, on 28th July 2018 (World Hepatitis Day) the National Viral Hepatitis Control Program was launched by the Ministry of Health and Family Welfare, Government of India. It is an integrated initiative for the prevention and control of viral hepatitis in India to achieve Sustainable Development Goal (SDG), which aims to end viral hepatitis by 2030.
Key Takeaways of the Hepatitis Drugs Market:
- The global hepatitis drugs market is expected to expand at a CAGR of 3.2% during the forecast period (2019–2027), owing to increasing government initiatives and drug development for hepatitis treatment.
- Among disease type, Hepatitis B is expected to hold major revenue share in 2026, owing to increasing global prevalence of hepatitis B. For instance, according to world health organization (WHO) estimates, in 2015, 257 million people were living with chronic hepatitis B infection, and 8, 87, 000 deaths occurred due to hepatitis B globally.
- Major players operating in the global hepatitis drugs market include Merck & Co. Inc., Gilead Sciences Inc., AbbVie Inc., Bristol Myers Squibb Company, F. Hoffmann-La Roche Ltd., LAURUS Labs, Zydus Cadila, Hetero Healthcare Limited, GlaxoSmithKline PLC., and Cipla Inc.
